drugset / Trial / NCT00291187

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

NCT00291187

Phase 3 Completed 411 enrolled Vanda Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of VEC-162 compared to placebo to improve sleep parameters in a model of insomnia.

Timeline

Start
2006-02
Primary completion
2006-08
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject tasimelteon Small molecule 20 mg Oral
Subject tasimelteon Small molecule 50 mg Oral
Subject tasimelteon Small molecule 100 mg Oral

Indications